Novo Nordisk’s diabetes drug also lowers heart risks

June 15, 2016 News BioVox

Since Eli Lilly and Boehringer Ingelheim demonstrated that their diabetes pill Jardiance lowers the risk of cardiovascular complications, competitors such as Merck, Pfizer and Novo Nordisk have been quick to develop drugs with similar effects. Novo now seems to have reached that goal. The Danish diabetes specialist reports that their injectable GLP-1 receptor agonist Victoza cuts cardiovascular risks by 13% and lowers deaths from heart disease by 22%. With those features, Victoza effectively becomes only the second diabetes treatment that lowers heart risks. Because half of all deaths in type 2 diabetes is due to cardiovascular complications, reducing the risk of heart disease is essential to their proper care.

“For us, this marks the beginning of a new era where our R&D focus will go beyond glucose control,” remarked Mads Krogsgaard Thomsen, CSO at Novo. Drugs such as Victoza change the perspective on type 2 diabetes from merely controlling blood sugar levels to a more integrative management of risks of complications.

While physicians and researchers praised Victoza’s consistency and robustness in clinical trials, investors were slightly disappointed by the size of the effect. Not reaching the market expectation of mid-to-high teens percentage in decrease of heart problem risk, Novo’s shares dropped about 5%.

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter